sellWeak cluster of 310b5-1 plan
SATO VICKI L sold $31k of DNLI
director at Denali Therapeutics Inc.. 1,020 shares at an average of $30.00, traded Nov 7, 2024, filed Nov 12, 2024.
Warning score
15Value
$31k
1,020 shares
Holdings after
111,056
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001714899-24-000217, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 7, 2024 | SOpen-market sale Common Stock10b5-1 | -1,020 | $30.00 | $31k | 111,056 | Nov 12, 2024 |
Related signals
Other insiders at Denali Therapeutics Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 40Moderate | sell 310b5-1 | DNLI Denali Therapeutics Inc. | Schenkein David P director | $1.9M | 59,441 | |
| 12Weak | sell 310b5-1 | DNLI Denali Therapeutics Inc. | Schuth Alexander O. COFO and Secretary | $465k | 15,558 | |
| 19Weak | sell 410b5-1 | DNLI Denali Therapeutics Inc. | SATO VICKI L director | $83k | 3,080 | |
| 28Weak | sell 210b5-1 | DNLI Denali Therapeutics Inc. | Watts Ryan J. President and CEO | $1.1M | 40,000 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.